Shared safety profile All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists across both manufacturers carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
J., Gallwitz, B., Schmidt, W
73 A twomonth trial ( n = 110) reported that 1500 mg/day metformin was superior to fenugreek for improving BMI, WHR, insulin resistance, fasting blood glucose, and menstrual regularity
Patients with complex medical historiesrecent cardiac events, severe kidney disease, diabetic gastroparesis, or multiple comorbiditiesmay benefit from in-person evaluation before initiating GLP-1
It may also affect where your ligaments and tendons join to your bones, and cause pain in your feet, legs, hips, ribs, and shoulders